Track topics on Twitter Track topics that are important to you
The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
INCB050465, INCB050465, Ruxolitinib
Not yet recruiting
Published on BioPortfolio: 2016-03-25T06:53:23-0400
The purpose of this study is to assess the objective response rate with INCB050465 treatment compared to idelalisib treatment in subjects with relapsed or refractory follicular lymphoma.
The purpose of this study is to evaluate the safety and efficacy of INCB050465 administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and...
The purpose of this study is to assess the impact of INCB050465 on the signs and symptoms of Sjögren's syndrome (SS).
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of INCB050465 in the treatment of Japanese participants diagnosed with previously-treated B-cell lym...
Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, INCB05046...
To estimate survival in Swedish and Norwegian myelofibrosis (MF) patients who received ruxolitinib.
After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may pre...
Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or...
Leukemic transformation is an unfavorable event emerging in a minority of patients with myelofibrosis (MF) and carrying a poor prognosis. Patients with post-MF acute myeloid leukemia (AML) may be trea...
Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course. Panob...
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.